Category Archives: Prostate Cancer

Enzalutamide monotherapy in Hormone-Naïve Prostate Cancer

Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer.

Posted in Active Surveillance, Hormonal Blockade, Metastatic Disease, Prostate Cancer, Treatments for Prostate Cancer | Tagged , , | Leave a comment

Cryo Immuno Therapy Part 3

Part 3 of the lecture about Cryo Immune Therapy given by Dr. Israel  Barken from the Prostate Research and Education Foundation.  Dr. Barken describes Cryo immunotherapy. The reasons why there are no consistent immune response after cryoablation are discussed.  Suggestions for … Continue reading

Posted in Cryo Immunotherapy, Cryoablation, Immune Therapy, Metastatic Prostate Cancer Disease, Prostate Cancer, Treatments for Prostate Cancer | Leave a comment

Cryo Immunotherapy Part 2

Part 2 of the lecture about Cryo Immune Therapy given by Dr. Israel  Barken from the Prostate Research and Education Foundation.  Dr. Barken describes Cryo immunotherapy. The reasons why there are no consistent immune response after cryoablation are discussed.  Suggestions … Continue reading

Posted in Cryo Immunotherapy, Cryoablation, Prostate Cancer, Treatments for Prostate Cancer | Leave a comment

Cryoablation Immuno Therapy

Clinical Study Phase I Cryoimmunotherapy against Metastatic prostate Cancer Disease. Dr. Israel Barken, the Medical Director of the Prostate Cancer Research and Education, presents a clinical study phase I, featuring cryosurgery plus immuno-Modulator – Cyclophosphamide and Anti CTLA 4 Antibodies- … Continue reading

Posted in Castration Resistant Prostate Cancer, Clinical Trials, Immune Therapy, Prostate Cancer, Treatments for Prostate Cancer, Vaccine | Leave a comment

Percentage Involved Core Length and Risk of Recurrence After Radical Prostatectomy

Article: Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy. Author:  Anthony V. D’Amico Source: Clinical Genitourinary Cancer.  March 5, 2015

Posted in Biopsy, Prognosis, Prostate Cancer, PSA, Survival prostate cancer, Treatments for Prostate Cancer | Leave a comment

Circulating Epithelial Tumor Cells and Tumor Spheres

Circulating Epithelial Tumor Cells (CETC) and Tumor Spheres. Discussion with Prof. Katharina Pachmann, Ph.D, M.D who is the medical Doctor in Jena University Hopital’s Department of Experimental Hematology and Oncology.  She is an expert on Circulating Epithelial Tumor Cells. The … Continue reading

Posted in Cancer Stem Cells, CETC, CTC, Prognosis, Prostate Cancer, Treatments for Prostate Cancer, Tumor Spheres | Leave a comment

Phase III Prostvac Clinical Study

Immune Therapy is an important tool for advanced prostate cancer disease, especially in older patients for whom chemotherapy is excluded because of other serious medical problems. Dr. Barken presents the Prostvac Clinical Study Phase III with a video clip featuring … Continue reading

Posted in Active Surveillance, Ask Dr. Barken, Castration Resistant Prostate Cancer, Clinical Trials, Immune Therapy, Metastatic Disease, Prostate Cancer, PSA | Leave a comment

Long Term Results of Optimized Focal Cryotherapy

Long Term Results of Optimized Focal Cryotherapy These days, there is a lot of interest in using focal therapy for prostate cancer. There are a number of modalities to achieve the destruction of the tumor locally within the prostate. Obviously … Continue reading

Posted in Active Surveillance, Focal Therapy, Prostate Cancer, Treatments for Prostate Cancer | Tagged , , , | Leave a comment

New Prostate Cancer Immunotherapy- Prostvac

Dr. Barken introduces the New Prostate Cancer Immune Therapy for earlier stages of Prostate Cancer.  Please watch the video below and see what  he learned at the National Cancer Institute recent conference mentioned above. Dr. James Gulley explains the Prostvac … Continue reading

Posted in Clinical Trials, Immune Therapy, Prostate Cancer, PSA, Treatments for Prostate Cancer | Tagged | Leave a comment

Enzalutamide and Prostvac for patients with PSA only disease after primary treatment

This very significant development could become the standard treatment for prostate cancer in the future.   Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer. NIH Study- Recruiting- ClinicalTrials.gov  Identifier: NCT01875250

Posted in Immune Therapy, Prostate Cancer, PSA, Radiation Therapy, Radical Prostatectomy | Leave a comment